(To see other currencies, click on price)
MORE ABOUT THIS BOOK
Main description:
The problems associated with the pharmacologic and physiologic regulation of neuromuscular transmission and of the morphofunctional organization of neuromuscular junctions have attracted a wide range of investigators. Numerous handbooks, monographs, and reviews are devoted to this subject. At the same time, many fundamental and applied aspects of this trend continue to progress succesfully. In recent years, new experimental and clinical data on the structure and function of neuromuscular junctions have been gained, and new, more perfect neuromuscular blocking agents have been designed. It is these data that the present handbook mainly deals with. A considerable number of chapters have been written by authors from eastern Europe. This was done intentionally since much of their work has previously been published only in their own languages, and is thus inaccessible to most Western readers. This is why some of the data included in the volume are not quite the latest, but they contain fruitful ideas or important results and are of value for further progress in the pharmacology of neuromuscular transmission. Naturally, the methodological level of the investigations differs, depending on when they were carried out. The handbook contains a number of selected chapters on the pharmacology of neuromuscular junctions; they comprise data otherwise insufficiently reviewed or not dealt with at all. They furthermore reflect the up-to-date state of the problem and probable directions of further developments in this field. D. A. KHARKEVICH Contents CHAPTER 1 Neuromuscular Blocking Agents: General Considerations D. A. KHARKEVICH . . . . . . . . . . . . . . . .
Contents:
1 Neuromuscular Blocking Agents: General Considerations.- 2 The End-Plate Acetylcholine Receptors: Structure and Function.- A. Introduction.- I. Scope of Review.- II. Perspective of the Junctional Acetylcholine Receptor.- III. Some Particularly Interesting Questions.- B. Molecular Properties of the Acetylcholine Receptor.- I. Purification.- II. Subunits and Stoichiometry.- III. Physical Properties.- IV. Reconstitution, Flux, and Planar Lipid Bilayers.- C. The 43K Protein.- Receptor Mobility.- D. Multiple Binding Sites and Multiple Affinity States.- I. Multiple Sites for Ligand Interaction.- II. The Three-State Model.- III. The Agonist Binding Site.- IV. Noncompetitive Blocking Agents.- E. Three-Dimensional Structure.- I. Biochemical Characterization.- II. Transmembrane Orientation.- III. Model.- F. Biochemical Control Over Receptor Activity: Phosphorylation, Methylation, and Glycosylation.- G. Summary and Conclusions.- References.- Pharmacodynamics and Pharmacokinetics of Neuromuscular Blocking Agents.- 3 On the Principles of Postsynaptic Action of Neuromuscular Blocking Agents.- A. Introduction.- B. Mechanisms of Action and Experimental Criteria for Them.- I. Range of Conditions of Tests.- II. Measurement of Binding.- III. Measurements of Response.- IV. Tests for Competitive Antagonism.- V. Tests for Noncompetitive Mechanisms.- C. The Mechanism of Action of Agonists.- I. Structure of the Receptor Ion Channel.- II. Opening of the Ion Channel by Agonists.- III. The End-Plate Current.- IV. Desensitization.- D. Nondepolarizing Neuromuscular Blocking Agents: Tubocurarine and Similar Drugs.- I. Numbers of Binding Sites.- II. Depolarization by Tubocurarine.- III. Inhibition of Equilibrium Responses.- IV. Binding of Tubocurarine and Similar Agents.- V. Evidence Concerning Nonequivalence of Binding Sites.- VI. Kinetics of Competitive Action.- VII. Ion Channel Block by Nondepolarizing Antagonists.- VIII. Competitive Block Under Physiological Conditions.- E. Nondepolarizing Neuromuscular Blocking Agents: Miscellaneous Agents of Low Specificity.- I. Some Drugs and Possible Mechanisms.- II. Block (Selective or Otherwise) of Ion Channels.- III. Reduction of Single-Channel Conductance.- IV. Enhancement of Desensitization.- V. Other Mechanisms: Correlations with Lipophilicity.- F. Depolarizing Blocking Agents.- I. Some Possible Modes of Action.- II. Sodium Channel Inactivation.- III. Changes in Intracellular Ion Concentration.- IV. Desensitization, Channel Block and "Dual Block".- G. Conclusions.- References.- 4 On the Hydrophobic Interaction of Neuromuscular Blocking Agents with Acetylcholine Receptors of Skeletal Muscles.- A. Introduction.- B. The Effect of Hydrophobic Radicals on the Mode of Action.- I. N-1-Adamantyl Derivatives.- II. Quaternary Ammonium Compounds with Adamantyl Radicals in Various Parts of the Molecule.- III. Alterations of the Mode of Action Evoked by Gradual Increase in Hydrophobicity.- C. The Effect of Hydrophobic Radicals on the Activity.- I. The Role of the Initial Mechanism of Action.- II. The Role of the Stereochemical Structure of Cationic Groups.- D. The Effect of Hydrophobic Radicals on the Main Pharmacologic Action.- E. Conclusions.- References.- 5 Prejunctional Actions of Cholinoceptor Agonists and Antagonists, and of Anticholinesterase Drugs.- A. Introduction.- B. Cholinoceptor Agonists and Antagonists, and Anticholinesterase Drugs.- I. Repetitive Antidromic Nerve Activity.- II. Tetanic Fade and Rundown of Trains of Nerve-Evoked Responses.- III. Is There Feedback Control of Transmitter Release?.- IV. Summary and Conclusions.- References.- 6 On the Comparative Sensitivity of Acetylcholine Receptors of Various Groups of Skeletal Muscles to Neuromuscular Blocking Agents.- A. Introduction.- B. On the Order of Skeletal Muscle Relaxation in Humans Under the Influence of Neuromuscular Blocking Agents.- I. Investigations on Anesthetized Patients.- II. Investigations on Volunteers.- C. Factors Which May Affect the Sensitivity of End-plate Acetylcholine Receptors to Neuromuscular Blocking Agents.- I. Structure of Skeletal Muscles.- II. Blood Circulation in the Skeletal Muscles.- III. Temperature of Skeletal Muscles.- IV. Acid-Base Equilibrium.- V. Lability of Neuromuscular Junctions.- VI. Site and Mode of Action of Neuromuscular Blocking Agents.- VII. Chemical Structure of Neuromuscular Blocking Agents.- D. Conclusions.- References.- 7 Antimuscarinic and Ganglion-Blocking Activity of Neuromuscular Blocking Agents.- A. Antimuscarinic Activity.- I. Introduction.- II. Comparative Characteristics of Antimuscarinic Activity of Neuromuscular Blocking Agents.- III. Mechanism of Antimuscarinic Action of Neuromuscular Blocking Agents.- IV. Some Other Possible Mechanisms of Cardiovascular Side Effects of Neuromuscular Blocking Agents.- V. Conclusions.- B. Ganglion-Blocking Activity.- I. Introduction.- II. Comparative Characteristics of Ganglion-Blocking Activity of Neuromuscular Blocking Agents.- III. Conclusions.- References.- 8 The Interaction of Neuromuscular Blocking Agents With Human Cholinesterases and Their Binding to Plasma Proteins.- A. Introduction.- B. Determination of Cholinesterase Activity.- C. Determination of Protein Binding.- D. Hydrolysis of Neuromuscular Blocking Agents by Cholinesterases.- E. Inhibition of Human Acetyl- and Butyrylcholinesterase by Neuromuscular Blocking Agents.- F. Binding of Neuromuscular Blocking Agents by Plasma Proteins.- G. Summary and Conclusions.- References.- 9 On the Effect of Neuromuscular Blocking Agents on the Central Nervous System.- A. Introduction.- B. Intravascular Administration of Neuromuscular Blocking Agents.- I. The Effect on Conditioned Reflexes.- II. The Effect on the Electroencephalogram.- III. The Effect on Interneuronal Transmission in the Afferent Pathways.- IV. The Effect on the Brain Stem.- V. The Effect on the Spinal Cord.- VI. The Effect on Reflex Responses of the Arterial Pressure.- VII. The Interaction of Neuromuscular Blocking Agents with Other Neurotropic Drugs.- C. Conclusions.- References.- 10 Biodegradation and Elimination of Neuromuscular Blocking Agents.- A. Introduction.- B. Ester Hydrolysis.- I. Suxamethonium.- II. Pancuronium.- III. Vecuronium.- C. Azo Fission.- Fazadinium.- D. Hofmann Elimination.- Atracurium.- References.- On the Relationship Between the Chemical Structure and the Neuromuscular Blocking Activity.- 11 Methods for the Experimental Evaluation of Neuromuscular Blocking Agents.- A. Introduction.- B. Evaluation of Neuromuscular Blocking Activity.- C. Evaluation of Toxicity.- D. Conclusions.- References.- 12 Steroid Derivatives.- A. Introduction.- B. Neuromuscular Blocking Activity.- I. Androstane Derivatives.- II. D-Homoazaandrostanes and Androstenes.- III. 4-Azaandrostanes.- IV. Miscellaneous Azasteroids.- V. Pregnane Derivatives.- VI. Conessine Derivatives.- VII. Cholane and Norcholane Derivatives.- VIII. Miscellaneous Steroids.- C. Onset and Duration of Neuromuscular Blocking Effect.- D. Conclusions.- References.- 13 The Derivatives of Carboxylic Acids.- A. Introduction.- B. The Derivatives of Truxillic Acids.- I. Bisquaternary Ammonium Derivatives of Basic Esters of Truxillic Acids.- II. Bisquaternary Ammonium Salts of ?-Truxillic Acid Aminoalkylamides.- III. Bistertiary Ammonium Salts of ?-Truxillic Acid Aminoalkylamides.- C. The Derivatives of Cinnamic and Benzoic Acids.- I. Cinnamic Acid Derivatives.- II. Benzoic Acid Derivatives.- D. The Derivatives of Aliphatic Dicarboxylic Acid Esters.- I. Neuromuscular Blocking Action.- II. Hydrolysis by Cholinesterases.- E. Conclusions.- References.- 14 Quinuclidinium Compounds.- A. Introduction.- B. Some Chemical Peculiarities of Quinuclidine.- C. Relationship Between the Structure and Neuromuscular Blocking Activity.- D. Pharmacology of Qualidilum.- E. Conclusions.- References.- 15 Derivatives of Terphenyl..- A. Introduction.- B. The Molecular Complementarity of the Nicotinic Acetylcholine Receptors and Dicationic Neuromuscular Blocking Agents.- C. Conformational Properties of Dicationic Neuromuscular Blocking Agents.- D. The Structure of Cationic Heads.- E. Directed Synthesis of Tercuronium.- F. Conclusions.- References.- 16 Delphinium Alkaloids.- A. Introduction.- B. Neuromuscular Blocking Activity.- C. Conclusions.- References.- Preclinical Pharmacology of New Neuromuscular Blocking Drugs.- 17 Bisquaternary Steroid Derivatives.- A. Introduction.- B. Chandonium and Its Analogs.- I. HS-342 and HS-467.- II. Chandonium Iodide.- III. New Derivatives.- C. Pipecuronium Bromide.- I. Introduction.- II. Action on the Neuromuscular Junction.- III. Other Pharmacologic Actions.- IV. Distribution, Excretion, and Metabolism.- D. RGH-4201.- I. Introduction.- II. Comparative Neuromuscular Blocking Effects.- III. Cardiovascular and Other Pharmacologic Actions.- IV. Pharmacokinetics.- V. Clinical Studies.- E. Conclusions.- References.- 18 Vecuronium (ORG-NC-45).- A. Introduction.- B. Mechanism of Action.- C. Potency and Time Course of Action: Cumulative Effects.- D. Pharmacokinetics.- E. Antagonism of Blocking Action.- F. Unwanted Effects.- I. Histamine Release.- II. Anticholinesterase Activity.- III. Ganglion Block.- IV. Block of Muscarinic Receptors.- V. Inhibitory Action on the Postganglionic Cardiac Vagus.- VI. Noradrenaline Release and Reuptake Block.- VII. Cardiovascular Effects.- G. Influence of Acid-base Balance.- H. Interactions with Other Drugs.- J. Conclusions.- References.- 19 The Derivatives of ?-Truxillic Acid.- A. Introduction.- B. Bisquaternary Salts of Aminoalkylester Derivatives: Anatruxonium, Cyclobutonium, Truxilonium, and Pyrocyclonium.- I. Neuromuscular Blocking Action.- II. Assessment of Side Effects.- III. Toxicologic Study.- C. Bisquaternary Salts of Aminoalkylamides: Dipyronium and Amidonium (in collaboration with E. Yu. Lemina).- I. Neuromuscular Blocking Action.- II. Assessment of Side Effects.- III. Toxicologic Study.- D. Bistertiary Salt of Aminoalkylamide: Pyrocurinum.- I. Neuromuscular Blocking Action.- II. Assessment of Side Effects.- III. Toxicologic Study.- E. Conclusions.- References.- 20 Adamantyl Compounds.- A. Introduction.- B. Diadonium.- I. Neuromuscular Blocking Action.- II. Assessment of Side Effects.- III. Toxicologic Study.- C. Decadonium.- I. Neuromuscular Blocking Action.- II. Assessment of Side Effects and Toxicity.- D. Conclusions.- References.- 21 Tercuronium..- A. Introduction.- B. Pharmacology of Tercuronium.- I. Neuromuscular Blocking Action.- II. Side Effects.- C. Toxicity of Tercuronium.- D. Conclusions.- References.- 22 Dioxonium..- A. Introduction.- B. Experimental.- I. Neuromuscular Blocking Activity.- II. Mechanism of Action.- III. Peculiarities of Effect on Repetitive Administration.- IV. Possible Side Effects.- V. Pharmacokinetics.- VI. Toxicology.- C. Conclusion.- References.- 23 Fazadinium Dibromide..- A. Introduction.- B. Azobisarylimidazo[1,2-a]pyridinium Dihalides.- Structure-Activity Relationships.- C. Animal Pharmacology of Fazadinium Dibromide.- I. Neuromuscular Blocking Properties.- II. Termination of Action.- III. Selectivity of Action.- D. Pharmacokinetics and Metabolic Fate of Fazadinium.- E. Conclusions.- References.- 24 Atracurium.- A. Introduction.- B. Neuromuscular Blocking Activity.- I. Chick Isolated Biventer Cervicis Preparation.- II. Anaesthetised Cats, Dogs and Rhesus Monkeys.- C. Changes in Acid-Base Balance.- D. Other Actions of Atracurium.- I. Effects on Autonomic Mechanisms.- II. Cardiovascular Effects.- III. Histamine Release.- E. Drug Interactions.- I. Premedicants.- II. Anaesthetics.- III. Hypotensive Drugs.- IV. Drugs Used for Resuscitation.- V. Antibiotics.- VI. Neuromuscular Blocking Agents.- F. Breakdown Products and Related Substances.- G. Cholinesterase Inhibition.- H. Conclusions.- References.- Clinical Pharmacology of New Neuromuscular Blocking Drugs.- 25 General Principles and Methods of Evaluation of Neuromuscular Blocking Agents in Anesthesiology.- A. Introduction.- B. Screening of Neuromuscular Blocking Agents in Conscious Subjects.- C. Assessment of Neuromuscular Blocking Agents in Anesthetized Subjects.- I. Pharmacodynamic Effects.- II. Pharmacokinetics.- D. Summary and Conclusions.- References.- 26 Neuromuscular Blocking Agents of Different Chemical Structure.- A. Introduction.- B. Bisquaternary Adamantyl-Containing Ester.- Diadonium.- C. ?-Truxillic Acid Derivatives.- I. Pyrocurinum.- II. Anatruxonium.- III. Cyclobutonium.- IV. Truxilonium.- D. Bisquaternary Derivative of Terphenyl.- Tercuronium.- E. Bisquaternary Derivative of Cyclic Acetosuccinylaldehyde.- Dioxonium.- F. Quinuclidine Derivative.- Qualidilum.- G. Combined Use of Neuromuscular Blocking Agents with Identical Modes of Action.- I. Diadonium plus Tercuronium.- II. Diadonium plus Tercuronium plus Diadonium.- III. Summary.- H. Conclusions.- References.- 27 Pipecuronium Bromide (Arduan)..- A. Introduction.- B. Clinical Pharmacodynamics.- I. The Neuromuscular Blocking Effect.- II. Effects on Heart Rate.- III. Hemodynamic Effects.- C. Clinical Pharmacokinetics.- I. Pharmacokinetics in Normal Patients.- II. Pharmacokinetics in Patients with Impaired Renal Function...- D. Clinical Use.- I. Intubation.- II. The Reversal of Pipecuronium Block with Anticholinesterases...- III. The Use of Pipecuronium in Patients with Impaired Cardiovascular Function.- IV. The Use of Pipecuronium in Patients with Impaired Renal Function.- V. Interaction Between Pipecuronium and Other Drugs Used in Anesthesiology and Surgery.- E. Conclusions.- References.- 28 Vecuronium (ORG-NC-45)..- A. Introduction.- B. Neuromuscular Blocking Characteristics.- I. Potency.- II. Duration of Action.- III. Cumulative Effects.- IV. Endotracheal Intubation.- C. Pharmacokinetics and Pharmacodynamics.- I. Comparison with Pancuronium.- II. Renal Failure.- D. Cardiovascular Effects.- I. Patients Without Cardiovascular Disease.- II. Patients Undergoing Coronary Artery Bypass Surgery.- III. Patients Undergoing Resection of a Pheochromocytoma.- E. Antagonism.- F. Conclusions.- References.- 29 Fazadinium Dibromide.- A. Introduction.- B. Clinical Pharmacology of Fazadinium.- I. Neuromuscular Blocking Properties.- II. Selectivity of Action.- III. Placental Transfer.- C. Conclusions.- References.- 30 Atracurium.- A. Introduction.- B. Quantitative Assessment.- I. Neuromuscular Blocking Activity.- II. Cardiovascular Effects.- III. Use with Volatile Anaesthetics.- C. Pharmacokinetics.- I. In Vitro Degradation.- II. Pharmacokinetic Profile.- D. Comparative Studies with Other Neuromuscular Blocking Agents...- I. Suxamethonium.- II. Tubocurarine and Dimethyltubocurarine.- III. Pancuronium and Vecuronium.- IV. Histamine-Releasing Potential of Atracurium, Dimethyltubocurarine and Tubocurarine.- V. Incremental Dosage of Atracurium and Vecuronium.- E. Specialised Uses.- I. Obstetric Anaesthesia.- II. Paediatric Anaesthesia.- III. Routine Anaesthesia in Elderly and Severely Ill Patients.- IV. Patients in Renal Failure.- V. Patients with Coronary Artery Disease.- VI. Infusion for Long Procedures Including Cardiopulmonary Bypass.- F. Conclusions.- References.- Antagonists of Neuromuscular Blocking Agents (Pharmacology and Clinical Use).- 31 Galanthamine..- A. Introduction.- B. Pharmacology of Galanthamine.- I. Anticholinesterase Activity.- II. Effect on Neuromuscular Transmission.- III. Antagonism Against Nondepolarizing Neuromuscular Blocking Agents.- IV. Effect on the Central Nervous System.- V. Effect on the Cardiovascular System.- VI. Effect on Respiration.- VII. Effect on Smooth Muscles.- VIII. Effect on the Superior Cervical Ganglion and Adrenals.- IX. General Effects and Toxicity.- X. Distribution: Pharmacokinetics of Galanthamine in Animals and Healthy Volunteers.- XI. Teratology and Embryotoxicity.- XII. Mutagenesis.- C. Clinical Application of Galanthamine.- I. Clinical Application as a Decurarizing Agent.- II. Treatment of Diseases of the Central and Peripheral Nervous Systems.- III. Application in Some Other Diseases.- D. Conclusions.- References.- 32 Chinothylinum..- A. Introduction.- B. Experimental Findings.- I. Anticholinesterase Activity.- II. Acetylcholine-Potentiating Activity.- III. Decurarizing Activity.- IV. Toxicity.- C. Clinical Findings.- D. Conclusion.- References.- 33 4-Aminopyridine Hydrochloride (Pymadin).- A. Introduction.- B. Actions on Excitable Membranes.- C. Actions on Neuromuscular Transmission.- I. Evoked Acetylcholine Release.- II. Spontaneous Acetylcholine Release.- III. Repetitive Nerve Stimulation.- D. Actions on Other Peripheral Synapses and Neuroeffector Junctions.- E. Actions on the Spinal Cord and Brain.- F. Actions on Endocrine Glands.- G. Actions on Muscle.- H. Cardiovascular System.- J. Clinically Useful Effects.- I. Human Pharmacokinetics.- II. Use of 4-Aminopyridine in Clinical Anaesthesia.- III. Experimental Clinical Use.- K. Conclusions.- References.- Subject Index V.V. Maisky.
PRODUCT DETAILS
Publisher: Springer (Springer-Verlag Berlin and Heidelberg GmbH & Co. K)
Publication date: December, 2011
Pages: 772
Weight: 1306g
Availability: Available
Subcategories: Pharmacology
From the same series
Roger G. Pertwee
Philip K. Moore
Kathleen M. Kantak
Alan Cowan
Hans-Georg Schaible
Arnold von Eckardstein
Mark A. Geyer
Botond Berde
Lorenzo A. Pinna
Arnold von Eckardstein
Mark A. Geyer
Anthony R.M. Coates
Vera Regitz-Zagrosek
Ursula F. Habenicht
Christoph Stein
Fabrizio Benedetti
Paolo Gresele
O. Eichler
Clive P. Page
Peter Ruben
G. Peters
Gary R. Lewin
Allison D. Fryer
Hans-Georg Joost
Vsevolod V. Gurevich
Hannsjorg W. Seyberth
Sharron H. Francis
George B. Koelle
Marc Humbert
G Kimmerle
Martha Merrow
Erich Gulbins
Martin C. Michel
Mathias Schwanstecher
Erich Gulbins
Martin F. Fromm
Ross G. Cameron
Hanns Mohler
Mark A. Geyer
F. Clementi
Peter Holzer
Gaetano Di Chiara
Anthony R. M. Coates
David S. Latchman
Siamon Gordon
Bernard Testa
Michael Oettel
B. Mayer
Klaus, von der Helm
Sheldon H. Preskorn
Lutz Hein
Heinz Nau
Stanley T. Crooke
J.M. Monti
Martin C. Michel
Vera Regitz-Zagrosek
Mark A. Geyer
G. Peters
Paolo Gresele
Manfred Gossen
Maynard B. Chenoweth
W. McD. Armstrong
Clive P. Page
Monika Schafer-Korting
Detlef Thieme
Fiona Cunningham
Vittorio Erspamer
Hans H. Ussing
Oskar Eichler
Ervin G. Erdös
S. Bettini
R.E.M. Bowden
John Morley
P.S. Randall
H. Winkler
R Jahn
J. Harenberg
F. Bachmann
D.J. Atherton
M.T. Jones
Frank A. Smith
Timothy D. Warner
Jochen Kuhlmann
James R. Gillette
Joel Bockaert
M. Chatterjee
A.P. Weetman
M. Sovak
Clive P. Page
James William Fisher
Hans-Georg Joost
D.I. Abramson
H.P. Witschi
R. Assan
Alfred J. Clark
J.M. van Rossum
Helmut Greim
Allison D. Fryer
Michael Oettel
M.L. Sears
R. Hess
P.E. Came
C.F. Arlett
H. Mehnert
W.N. Kelley
Luc P. Balant
Alan C. Sartorelli
Gregory R. Mundy
W. R. Martin
Peter Perlman
Michael B. Sporn
Harold C. Hodge
David R. Brown
C. Muller
J. Erik Jorpes
H.E. Voss
Peter Frederick Baker
Pedro Cuatrecasas
Laszlo Szekeres
Fritz Markwardt
R. Baserga
H. Vanden Bossche
Stephen H. Caldwell
Ronald T. Borchardt
Alain L. de Weck
Lawrence E. Bryan
T.J. Campbell
F. Lang
K. Bartmann
Donald B. Calne
E.M. Johnson
G.H. Hitchings
Arnold L. Demain
Eugen Dorzbach
U. Peters
M. Green
A. S. Milton
R. Baurain
Brian W. Fox
W. Bleifeld
P. Actor
H. Vanden Bossche
Victor P. Whittaker
Ullrich Trendelenburg
D. Janz
Börje Uvnäs
H.G. Baumgarten
J. A. Nathanson
Frederick C. Kauffman
S. Silver
Kurt Greeff
B. Babudieri
J.G. Banwell
T.T. Aoki
A.L. Jr. Ager
M. Ackenheil
M. Rocha e Silva
Carlo Patrono
Hamao Umezawa
W. Rogalski
G. R. Strichartz
E.C. Foulkes
P. Needleman
E. Anggard
H. Schmidt
C. Braestrup
L.G. Abood
D.A. Kharkevich
C.-Y. Lee
Charles D. Kochakian
Robert Charlier
A.C. Allison
I.H. Page
James R. Gillette
Hermann Blaschko
K.W. Bock
Dean H. Lockwood
A. Dickenson
Franz von Bruchhausen
P.F. D'Arcy
Robert J. Kavlock
Andrew C.G. Uprichard
P.J. Lefebvre
Mervyn J. Eadie
Franz Hefti
Ross G. Cameron
John G. Csernansky
Michael J. Kuhar
Hannsjorg W. Seyberth
Sharron H. Francis
Mathias Schwanstecher
Martin C. Michel
Martin R. Wilkins
Martin F. Fromm
Peter Redfern
Klaus Aktories
Jurgen Behrens
Harri U. Vainio
Michael Williams
Dennis W. Choi
Gaetano Di Chiara
Peter Jonas
Salvador Moncada
Stefan Bauer
Markus Schwaiger
Markus Schwaiger
Jurgen Schuttler
Hans-Georg Krausslich
Veit M. Flockerzi
Harald H.H.W. Schmidt
Thomas C. Sudhof
Eric Beitz
Kian Fan Chung
Andreas Michael Zeiher
Yuti Chernajovsky
Jack E. Henningfield
Giovanna Lombardi
Salvador Moncada
Florian Holsboer
Enno Klussmann
Clive P. Page
Bertil B. Fredholm
Ursula F. Habenicht
Fiona Cunningham
Monika Schafer-Korting
Matthias Gaestel
Volker A. Erdmann
Robert E. Kass
Harald Sitte
Detlef Thieme
Domenico Spina
Constance N. Wilson
Jack E. Henningfield
Eric Beitz
Harald H.H.W. Schmidt
Giovanna Lombardi
Hans-Georg Krausslich
Kian Fan Chung
Markus Schwaiger
Markus Schwaiger
Enno Klussmann
Anna M. Wobus
Jurgen Schuttler
Thomas C. Sudhof
Stefan Bauer
Yuti Chernajovsky
Andreas Michael Zeiher
Veit M. Flockerzi
Christoph Stein
Salvador Moncada
Salvador Moncada
Harald Sitte